low - Pharmaceutical demand is non-discretionary and largely insulated from GDP fluctuations. Generic prescriptions remain stable through recessions as patients prioritize essential medications. However, emerging markets revenue (~30% of total) shows moderate sensitivity to local GDP growth and currency fluctuations, particularly in Latin America and MENA regions where out-of-pocket spending dominates.

Rising rates increase financing costs on $8.9B debt load (0.97x D/E), though much is fixed-rate from merger financing. Higher rates compress valuation multiples for low-growth pharma stocks as investors rotate toward bonds. Conversely, strong FCF generation ($2B annually) enables debt paydown regardless of rate environment, reducing refinancing risk. Rate sensitivity is moderate - impacts valuation more than operations.

value - Investors focus on 10.9% FCF yield, 1.3x P/S valuation, and debt paydown story. The 46% 1-year return reflects re-rating as merger integration progresses and deleveraging accelerates. Attracts deep value funds seeking mispriced turnarounds with hidden asset value in manufacturing network and biosimilar pipeline. Not a growth story - revenue declining 4.5% YoY due to pricing headwinds.